TSC Alert

Archive for the ‘Research Resources’ Topic

Now Accepting Nominations for Preclinical Testing

Nominations accepted until Friday, June 10, 2022  Interested principal investigators (PI) are invited to nominate candidate therapeutics for testing in the TSC Preclinical Consortium’s tumor models. Please complete the short nomination form, available on the TSC Alliance Preclinical Consortium webpage. The form requests no more than two pages of text and/or figures to describe the rationale for the compound and its mechanism of action for TSC. The lead PI must also submit an NIH-style biosketch. Nominations will be accepted until Monday, August 1, 2022.   Companies interested in nominating compounds and retaining confidentiality and ownership of the data should not utilize the nomination…

TSC Alliance® Partners with NeurologyLive™

The TSC Alliance has partnered with NeurologyLive to bring healthcare professionals treating neurological disorders the latest in research and practice. Check out our partner page. Subscribe to NeurologyLive to stay up to date on clinical trial news, FDA updates and more.

Repurposing Partnering Opportunity with Healx

Healx, a Cambridge, UK biotech, is focused on repurposing known molecules for rare diseases. As part of their Rare Treatment Accelerator (RTA) programme, Healx is looking to partner with academic institutions who have identified drug repurposing opportunities for rare diseases but who lack financial and clinical resources to take these all the way to patients.  Healx could help with this as part of their Rare Treatment Accelerator 2.0 (RTA).